

## Technology Advisory Committee D Interests Register

Topic [ID3834]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Scott Muir	Committee Member	Direct – Non-financial Professional	Dr Muir is Chairman of the Scottish Medicines Consortium and Chairman of the Glasgow and Clyde area Drugs and Therapeutics Committee	19/09/2023 23/11/2023	It was agreed that Dr Muir's declaration would not prevent him from participating in discussions on this appraisal
Giles Monnickendam	Committee Member	Direct - Financial	Giles has received honoraria and consulting fees from Janssen for advisory work in an unrelated indication (RR multiple myeloma)	20/09/2023	It was agreed that Giles' declaration would not prevent him from participating in discussions on this appraisal
David Meads	Committee Member	Non-financial Professional	The University of Leeds has received funding from Sanofi and Janssen for research in an unrelated area.	26/09/2023 28/11/2023	It was agreed that David's declaration would not prevent him from participating in discussions on this appraisal
Professor Andrew Jones	Clinical Expert	Direct – non-financial	<ul style="list-style-type: none"> <li>Andrew is a Member, NHS England Respiratory Medicine Clinical Reference Group Clinical 2016 – ongoing</li> <li>Member, NICE/NHSE Vertex CF modulator therapies Interim</li> </ul>	03/03/2023	It was agreed that Andrew's declaration would not prevent him

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
		Direct - financial	<p>Access Oversight Committee 2019-2022</p> <ul style="list-style-type: none"> <li>Local site sub-investigator on Vertex clinical studies</li> <li>NICE Cystic Fibrosis Guideline Committee Member 2015-2017 (national CF clinical guideline), 2020 (CF COVID guideline)</li> <li>Until recently Andrew was a trustee of the Cystic Fibrosis Trust</li> <li>Andrew was a speaker at a recent CF academy meeting which was sponsored by Vertex and for which he received travel and speaker fees.</li> <li>In the past he has received an independent competitive investigator grant from Vertex</li> </ul>	<p>12/10/2023</p> <p>14/12/2023</p>	from providing expert advice to the committee.
Andrew Lilley	Clinical Expert	Indirect - Professional	Andrew's trust and his department has been involved with Vertex but he has not personally been involved.	12/10/2023	It was agreed that Andrew's declaration would not prevent him from providing expert advice to the committee.
Dr Don Urquhart	Clinical Expert		<ul style="list-style-type: none"> <li>Dr Urquhart has previously received speaker fees from Vertex Pharmaceuticals</li> </ul>	10/08/2023	It was agreed that Dr Urquhart's declaration would not prevent him

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<ul style="list-style-type: none"> <li>Dr Urquhart has received fees for taking part in advisory boards for Vertex Pharmaceuticals and AbbVie Pharma.</li> <li>Dr Urquhart has been a principal investigator on a number of clinical trials undertaken by Vertex Pharmaceuticals</li> </ul>	14/12/2023	from providing expert advice to the committee.
Will Sullivan	Committee Member	Direct – Financial	Roche products – Will's previous employer - was paid for him to provide consultancy advice to Hoffmann-La Roche AG, for a different product and different indication to those on the matrix list, in the last 12 months.	27/11/2023	It was agreed that Will's declaration would not prevent him from participating in discussions on this appraisal